Capricor Therapeutics (CAPR) Other Accumulated Expenses (2022 - 2026)

Capricor Therapeutics' Other Accumulated Expenses history runs 5 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 1885.45% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 1885.45% YoY), while the FY2025 annual figure was $3.1 million, up 622.1% from the prior year.
• Other Accumulated Expenses was $4.0 million for Q1 2026 at Capricor Therapeutics, up from $3.1 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $4.0 million in Q1 2026 to a low of $10000.0 in Q4 2023.
• Historically, Other Accumulated Expenses has averaged $1.0 million across 5 years, with a median of $145457.5 in 2022.
• The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses tumbled 88.79% in 2023, then soared 26121.55% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $89234.0 in 2022, then sank by 88.79% to $10000.0 in 2023, then jumped by 4257.12% to $435712.0 in 2024, then soared by 622.1% to $3.1 million in 2025, then grew by 27.27% to $4.0 million in 2026.
• The last three Other Accumulated Expenses figures came in at $4.0 million (Q1 2026), $3.1 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.